ipilimumab + Nivolumab

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Uveal Melanoma

Conditions

Uveal Melanoma

Trial Timeline

Apr 1, 2016 → Jul 22, 2021

NCT ID

NCT02626962

About ipilimumab + Nivolumab

ipilimumab + Nivolumab is a phase 2 stage product being developed by Bristol Myers Squibb for Uveal Melanoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02626962. Target conditions include Uveal Melanoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05200988	Phase 2	Active	Mar 14, 2022	Sep 5, 2027	Urothelial Carcinoma
NCT04933903	Phase 2	Recruiting	Oct 5, 2021	Apr 1, 2026	Non Small Cell Lung Cancer
NCT04969887	Phase 2	Active	Aug 3, 2021	Mar 1, 2027	Advanced Biliary Tract Cancer
NCT04463368	Phase 1	Completed	Mar 8, 2021	Jul 26, 2024	Uveal Melanoma
NCT04717154	Phase 2	Completed	Jan 19, 2021	Dec 18, 2025	Prostatic Neoplasms, Castration-Resistant
NCT04124601	Phase 2	Completed	Jun 1, 2020	Mar 15, 2024	Rectal Cancer
NCT04118166	Phase 2	Completed	Oct 1, 2019	Apr 26, 2022	Soft Tissue Sarcoma
NCT03340129	Phase 2	Recruiting	Aug 14, 2019	Aug 1, 2029	Melanoma Stage Iv
NCT03682276	Phase 1/2	UNKNOWN	Mar 1, 2019	Dec 1, 2023	Hepatocellular Carcinoma
NCT03305445	Phase 1	Completed	May 14, 2018	Apr 1, 2021	Relapsed Diffuse Large B-Cell Lymphoma
NCT03425331	Phase 2	Terminated	Apr 10, 2018	Nov 28, 2021	Non-small Cell Lung Cancer
NCT03387761	Phase 1	Completed	Jan 15, 2018	Jan 7, 2025	Urothelial Carcinoma
NCT03333616	Phase 2	Active	Dec 28, 2017	Dec 31, 2026	Genitourinary Cancer
NCT03203473	Phase 2	Active	Oct 26, 2017	Jun 28, 2026	Renal Cancer
NCT03168464	Phase 1/2	Terminated	Oct 9, 2017	Mar 11, 2022	Non Small Cell Lung Cancer Metastatic
NCT02892734	Phase 2	Terminated	Sep 18, 2017	Feb 4, 2019	HER2/Neu Negative
NCT02923934	Phase 2	Completed	Aug 22, 2017	Dec 12, 2023	Gastrointestinal Cancer
NCT03146650	Phase 2	UNKNOWN	May 19, 2017	Aug 11, 2025	Major Salivary Gland Carcinoma
NCT03122522	Phase 2	Active	Apr 17, 2017	Apr 1, 2026	Metastatic Melanoma
NCT03043599	Phase 1/2	Completed	Feb 13, 2017	Nov 16, 2023	Small Cell Lung Cancer

Competing Products

20 competing products in Uveal Melanoma

See all competitors

Product	Company	Stage	Hype Score
Pembrolizumab + Lenvatinib	Eisai	Phase 2	52
Selumetinib, 100mg + Selumetinib, 125mg + Selumetinib, 150mg + Selumetinib, 175mg + Selumetinib, 200mg + Selumetinib, 225mg	AstraZeneca	Phase 1	33
Pembrolizumab + Entinostat	Merck	Phase 2	52
Pembrolizumab + Olaparib	Merck	Phase 2	52
Pembrolizumab 25 MG/1 ML Intravenous Solution	Merck	Phase 2	52
AEB071	Novartis	Phase 1	33
LXS196 + LXS196 and HDM201	Novartis	Phase 1	33
DYP688	Novartis	Phase 1/2	41
RAD001 (Everolimus) and Pasireotide (SOM230) LAR	Novartis	Phase 2	52
ranibizumab + triamcinolone acetonide	Novartis	Phase 2/3	65
Crizotinib	Pfizer	Phase 2	51
Dacarbazine + Sunitinib	Pfizer	Phase 2	51
AEB071 + MEK162	Pfizer	Phase 1/2	40
Binimetinib + Belinostat	Pfizer	Phase 2	51
Ipilimumab + Nivolumab	Bristol Myers Squibb	Phase 1	32
Nivolumab + Relatlimab	Bristol Myers Squibb	Phase 2	51
ZIV-Aflibercept + Cemiplimab	Sanofi	Phase 2	51
Ziv-Aflibercept	Regeneron Pharmaceuticals	Phase 2	51
XmAb®23104 + Yervoy® (ipilimumab)	ICON plc.	Phase 1	30
IDE196 + Binimetinib + Crizotinib	IDEAYA Biosciences	Phase 1/2	36

Other Products from Bristol Myers Squibb

DeucravacitinibApproved

Aripiprazole + Olanzapine + HaloperidolApproved

Irbesartan + CiprofibrateApproved

Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved

deucravacitinibApproved